Literature DB >> 23804712

Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control.

Michael Y Gerner1, Lynn M Heltemes-Harris, Brian T Fife, Matthew F Mescher.   

Abstract

Naive CD8 T cells proliferate in response to TCR and CD28 signals, but require IL-12 or type I IFN to survive and develop optimal effector functions. Although murine CTL generated in vitro in response to IL-12 or IFN-α had comparable effector functions, IL-12-stimulated cells were significantly more effective in controlling tumor in an adoptive immunotherapy model. They maintained high numbers and function, whereas IFN-α-stimulated cells declined in number and became exhausted. Consistent with this, IFN-α-stimulated cells in the tumor expressed higher levels of programmed death 1 (PD-1) inhibitory receptor than did IL-12-stimulated cells. When blocking Ab specific for the PD-L1 ligand of PD-1 was administered, the efficacy of IFN-α-stimulated CTL became comparable with that of IL-12-stimulated cells. Thus, IL-12 and IFN-α differentially program CD8 T cells to re-express distinct levels of PD-1 upon re-encountering Ag, resulting in IL-12-stimulated cells being less susceptible to exhaustion in the face of sustained tumor Ag.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23804712      PMCID: PMC3720703          DOI: 10.4049/jimmunol.1300652

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  CD8 T cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine.

Authors:  Julie M Curtsinger; Christopher M Johnson; Matthew F Mescher
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

Review 2.  Signals required for programming effector and memory development by CD8+ T cells.

Authors:  Matthew F Mescher; Julie M Curtsinger; Pujya Agarwal; Kerry A Casey; Michael Gerner; Christopher D Hammerbeck; Flavia Popescu; Zhengguo Xiao
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

3.  Expression of programmed death 1 ligands by murine T cells and APC.

Authors:  Tomohide Yamazaki; Hisaya Akiba; Hideyuki Iwai; Hironori Matsuda; Mami Aoki; Yuka Tanno; Tahiro Shin; Haruo Tsuchiya; Drew M Pardoll; Ko Okumura; Miyuki Azuma; Hideo Yagita
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

Review 4.  Negative regulation of T-cell function by PD-1.

Authors:  Yuan yuan Zha; Christian Blank; Thomas F Gajewski
Journal:  Crit Rev Immunol       Date:  2004       Impact factor: 2.214

5.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

6.  CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion.

Authors:  Peter Aichele; Heike Unsoeld; Marie Koschella; Oliver Schweier; Ulrich Kalinke; Smiljka Vucikuja
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

Review 7.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

Review 8.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

9.  PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.

Authors:  Christian Blank; Ian Brown; Amy C Peterson; Mike Spiotto; Yoshiko Iwai; Tasuku Honjo; Thomas F Gajewski
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

10.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.

Authors:  Ganesh A Kolumam; Sunil Thomas; Lucas J Thompson; Jonathan Sprent; Kaja Murali-Krishna
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

View more
  40 in total

1.  Absence of recipient C3aR1 signaling limits expansion and differentiation of alloreactive CD8+ T cell immunity and prolongs murine cardiac allograft survival.

Authors:  Douglas R Mathern; Julian K Horwitz; Peter S Heeger
Journal:  Am J Transplant       Date:  2019-01-14       Impact factor: 8.086

Review 2.  Regulation of antiviral T cell responses by type I interferons.

Authors:  Josh Crouse; Ulrich Kalinke; Annette Oxenius
Journal:  Nat Rev Immunol       Date:  2015-03-20       Impact factor: 53.106

Review 3.  T-cell exhaustion in allograft rejection and tolerance.

Authors:  Edward B Thorp; Christian Stehlik; M Javeed Ansari
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

4.  Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.

Authors:  C Bryce Johnson; Brian P Riesenberg; Bennett R May; Stuart C Gilreath; Guangfu Li; Kevin F Staveley-O'Carroll; Elizabeth Garrett-Mayer; Shikhar Mehrotra; David J Cole; Mark P Rubinstein
Journal:  Cancer Immunol Res       Date:  2015-08-21       Impact factor: 11.151

5.  Coinfection with Streptococcus pneumoniae negatively modulates the size and composition of the ongoing influenza-specific CD8⁺ T cell response.

Authors:  Lance K Blevins; John T Wren; Beth C Holbrook; Sarah L Hayward; W Edward Swords; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2014-10-13       Impact factor: 5.422

6.  Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-γ.

Authors:  Lin Lin; Patricia Rayman; Paul G Pavicic; Charles Tannenbaum; Thomas Hamilton; Alberto Montero; Jennifer Ko; Brian Gastman; James Finke; Marc Ernstoff; C Marcela Diaz-Montero
Journal:  Cancer Immunol Immunother       Date:  2018-12-14       Impact factor: 6.968

7.  IL-12 Signals through the TCR To Support CD8 Innate Immune Responses.

Authors:  Nicholas P Goplen; Vikas Saxena; Karin M Knudson; Adam G Schrum; Diana Gil; Mark A Daniels; Rose Zamoyska; Emma Teixeiro
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

8.  Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy.

Authors:  Masahiro Azuma; Yohei Takeda; Hiroko Nakajima; Haruo Sugiyama; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

Review 9.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.

Authors:  Amy E Moran; Fanny Polesso; Andrew D Weinberg
Journal:  J Immunol       Date:  2016-08-08       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.